Outcomes in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial

被引：11
|
作者：
Sternberg, Cora N.
De Bono, Johann Sebastian
Chi, Kim N.
Fizazi, Karim
Mulders, Peter
Hirmand, Mohammad
Forer, David
Scher, Howard I.
机构：
[1] San Camillo & Forlanini Hosp, Rome, Italy
[2] Inst Canc Res, Sutton, Surrey, England
[3] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada
[4] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
[5] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
[6] Medivation Inc, San Francisco, CA USA
[7] Mem Sloan Kettering Canc Ctr, Sidney Kimmel Ctr Prostate & Urol Canc, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial
    Loriot, Yohann
    Fizazi, Karim
    De Bono, Johann Sebastian
    Forer, David
    Hirmand, Mohammad
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial†
    Sternberg, C. N.
    de Bono, J. S.
    Chi, K. N.
    Fizazi, K.
    Mulders, P.
    Cerbone, L.
    Hirmand, M.
    Forer, D.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2014, 25 (02) : 429 - 434
  • [3] A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Powles, Thomas
    Fizazi, Karim
    Gillessen, Silke
    Drake, Charles G.
    Rathkopf, Dana E.
    Narayanan, Sujata
    Green, Marjorie C.
    Mecke, Almut
    Schiff, Christina
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A phase Ib trial of enzalutamide with venetoclax in metastatic castration-resistant prostate cancer (mCRPC).
    Gopalakrishnan, Dharmesh
    Kirk, Jason
    Davis, John
    George, Saby
    Levine, Ellis Glenn
    Beumer, Jan Hendrik
    Appleman, Leonard Joseph
    Tang, Dean
    Chatta, Gurkamal S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide
    Baciarello, Giulia
    Sternberg, Cora N.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 106 : 14 - 24
  • [6] IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Sweeney, Christopher J.
    Gillessen, Silke
    Rathkopf, Dana
    Matsubara, Nobuaki
    Drake, Charles
    Fizazi, Karim
    Piulats, Josep M.
    Wysocki, Piotr J.
    Buchschacher, Gary L., Jr.
    Doss, Jennifer
    Mariathasan, Sanjeev
    Kadel, Edward E.
    Yuen, Kobe
    Datye, Asim
    Rasuo, Grozdana
    Tayama, Darren
    Williams, Patrick
    Powles, Thomas
    CANCER RESEARCH, 2020, 80 (16)
  • [7] A phase I/VII trial of enzalutamide plus the glucocorticoid receptor antagonist mifepristone for patients with metastatic castration-resistant prostate cancer (mCRPC).
    Szmulewitz, Russell Zelig
    Nabhan, Chadi
    O'Donnell, Peter H.
    Kach, Jacob
    Karrison, Theodore
    Martinez, Elia
    Stadler, Walter Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer
    Sternberg, Cora N.
    FUTURE ONCOLOGY, 2019, 15 (13) : 1437 - 1457
  • [9] PHASE 3 TRIAL OF PEMBROLIZUMAB AND ENZALUTAMIDE VERSUS ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) (KEYNOTE-641)
    Graff, Julie Nicole
    Burgents, Joseph
    Liang, Li Wen
    Stenzl, Arnulf
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A210 - A210
  • [10] COST-UTILITY ANALYSIS OF ENZALUTAMIDE FOR PATIENTS WITH PREVIOUSLY TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Vicente, C.
    Babashov, V
    Husein, F.
    Saad, F.
    Naidoo, S.
    Holmstrom, S.
    VALUE IN HEALTH, 2014, 17 (03) : A89 - A90
12345